Actively Recruiting
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Led by N.N. Alexandrov National Cancer Centre · Updated on 2026-03-16
120
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.
CONDITIONS
Official Title
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-75 years
- Histologically confirmed serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Ability to undergo diagnostic laparoscopy or cytoreductive surgery
- Presence of homologous recombination deficiency (HRD)
- No contraindications to chemotherapy or bevacizumab
- Signed informed consent to participate in the study
You will not qualify if you...
- Presence of another active malignant invasive cancer
- Pregnancy or lactation
- Disease progression during treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
N.N. Alexandrov National Caner Centre
Minsk, Lesnoy, Belarus, 223040
Actively Recruiting
Research Team
H
Hanna Trukhan
CONTACT
S
Sergey Mavrichev
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here